After five years on the FDA Drug Shortage List, the injectable TRIESENCE® (triamcinolone acetonide injectable suspension) 40 mg/mL has been relaunched. TRIESENCE is a preservative-free corticosteroid approved by the FDA for visualization during vitrectomy, and treatment of ocular inflammation that is unresponsive to topical corticosteroids.
In vitrectomies, it provides a white backdrop that improves visualization of the retina and vitreous membranes, while its “potent anti-inflammatory properties also play a critical role in managing severe ocular inflammatory conditions,…reducing swelling, pain, and the risk of long-term damage,” John W. Kitchens, MD, an ophthalmologist and vitreoretinal surgeon with Retina Associates of Kentucky, said in the press release.